Rekah Pharmaceutical Industry Ltd.

rekah.co.il

High-Tech Company
Public Company

(TASE: REKA)

TECH VERTICALS

Cosmetics, Dermatology, Food Additives, Life Sciences, Marketing Tech, MedTech, Pharmaceuticals, Skin Care, Therapeutics

General Data

Sector	Biomed
Company Stage:	Revenue Growth
Established	1941
Number of Employees	450
Reg. Number:	abCDe

DESCRIPTION

Rekah Pharmaceutical Industry is a public company traded on the Israel Stock Exchange. The Group owns a number of designated subsidiaries (Vitamed, Ophir, Center-Pharm) which are engaged in the manufacture, marketing, sale and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements. Established in 1941, Rekah boasts a long record of pioneer activity in Israel’s pharmaceutical industry, and has amassed vast and diverse experience in the development, production and sale of generic drugs.

TECHNOLOGY

The factory manufactures approximately 250 different pharmaceuticals, including medicines in solid forms (tablets, encased tablets and capsules), liquid forms (syrups, nasal and other solutions), and oily forms (ointments, suppositories and creams). These pharmaceuticals include a variety of generic therapeutic products and as well as products bearing trade names in the following pharmaceutical categories: some 40 % of the products made are sold by prescription only. The rest are sold over-the-counter (OTC). Most products bear brand names.

Products and Phases

Product	Phase
BAMYXIN EYE OINTMENT	Approved Israel
Short term treatment of superficial external ocular infections
DESOREN	Approved Israel
For the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics.
RONEXIN	Approved Israel
Psychotic disorders, particulary to produce a tranquillizing effect on hyperactive or excited psychotic patients and in patients suffering from anxiety, tension and behavioural disorders

ESTIMATED ANNUAL SALES

Year	Amount
2021	500
2020	490
2019	480
2013	470
2005	460
2004	450
2003	440

	TARGET MARKETS
	Health Funds, Pharmacies, Hospitals, Retirement Homes, National Medical Healthcare Services Retail Food Chains.

	BUSINESS MODEL
	B2B

COMPETITORS

Teva

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
8BCC77DE-1F7A-E111-AC59-00155D32A403		Rekah Pharmaceutical Industry Ltd.
8BC86FE4-1F7A-E111-AC59-00155D32A403	Subsidiary	Vitamed Pharmaceuticals Industries Ltd.	Rekah Pharmaceutical Industry Ltd.	Acquired/Merged

REMARKS

Date	Remark
	Rekah maintains several manufacturing sites like Vitamed (acquired in 03/2003) located in Binyamina, Israel, and also owns Center Pharm, a chain of commercial pharmacies in Israel.

CONTACT INFO

Expand / Collapse All

Main Address: Holon, Israel

Address	30 Hamelacha St.
City	Holon
Country	Israel
Zip	5881904

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Lod, Israel

Address	1 Bat-Sheva St.
POB	799
City	Lod
Country	Israel
Zip	7110604

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Mordechai Arye Elgrably	CEO
Mr. Yuval Elgrably	Deputy CEO & VP, Business Development
Mr. Lior Haalman	CFO
Mr. Guy Zangi	VP, International Sales & Business Development
Mr. Nir Sella	CEO, Tree of Life Pharma
Mr. Yaacov Elgrably	CEO, Ophir & Shalpharm Medicines & Cosmetics Ltd.
Ms. Einat Natanson	Marketing Manager

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Chairman, P.C.B. Technologies Ltd.
abC Defghij	Board Member	CEO & Founder, FIMI
abC Defghij	Board Member	CEO, Rekah Pharmaceutical Industry Ltd.
abC Defghij	Board Member	Former CEO, Rekah Pharmaceutical Industry

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Apr. 15, 2015

Revenue Growth

abCDe

FIMI bought 42.5% of the company (with an addjustment mechanism that can bring it up to 51.5%) for $20.5 (NIS 80m) 04/2018: The 2015 agreement's term were fulfilled and FIMI was allocated additional shares of the company with no payment. It now holds 51.6% of the company.

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Private Equity Fund	abCDe	FIMI bought 42.5% of the company (with an adjustment mechanism that can bring it up to 51.5%) for $20.5M (NIS 80m). 04/2018: The 2015 agreement's term were fulfilled and FIMI was allocated additional shares of the company with no payment. It now holds 51.6% of the company.

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Mar. 11, 2014	Second Public Offering	TASE	abCDe	abCDe	Debentures.
Jun. 01, 1995	IPO	TASE	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors